Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system

Journal of Virology

Volumn 89, Issue 9, 2015, Pages 5176-5179

  Yuan, Ming ^a   Zhang, Wensheng ^b,c   Wang, Jun ^a   Al Yaghchi, Chadwan ^a   Ahmed, Jahangir ^a   Chard, Louisa ^a   Lemoine, Nick R ^a,d   Wang, Yaohe ^a,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b SOOCHOW UNIVERSITY   (China)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; GREEN FLUORESCENT PROTEIN; GUIDE RNA; POXVIRUS VECTOR; RED FLUORESCENT PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

A46R GENE; ARTICLE; CLONING VECTOR; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DNA MODIFICATION; DOUBLE STRANDED DNA BREAK; GENE DELETION; GENE SEQUENCE; GENE TARGETING; HOMOLOGOUS RECOMBINATION; MOLECULAR CLONING; N1L GENE; NONHUMAN; PRIORITY JOURNAL; RNA EDITING; SHUTTLE VECTOR; VACCINIA VIRUS; VIRUS GENE; VIRUS GENOME; VIRUS MUTANT; VIRUS PLAQUE; CRISPR CAS SYSTEM; GENETIC RECOMBINATION; GENETICS; MOLECULAR BIOLOGY; PHARMACEUTICS; PROCEDURES;

VACCINIA VIRUS; VARIOLA VIRUS;

CRISPR-CAS SYSTEMS; GENOME, VIRAL; MOLECULAR BIOLOGY; RECOMBINATION, GENETIC; TECHNOLOGY, PHARMACEUTICAL; VACCINIA VIRUS;

EID: 84928562543     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00339-15     Document Type: Article

References (27)

1. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu SL, Corey L. 1991. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567-572. http://dx.doi.org/10.1016/0140-6736(91)91636-9.
2. DiPaola RS, Chen Y, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G. 18 December 2014. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol http://dx.doi.org/10.1016/j.eururo.2014.12.010.
3. Guo ZS, Bartlett DL. 2004. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 4:901-917. http://dx.doi.org/10.1517/14712598.4.6.901.
4. Moss B. 2013. Reflections on the early development of poxvirus vectors. Vaccine 31:4220-4222. http://dx.doi.org/10.1016/j.vaccine.2013.03.042.
5. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. 2011. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477:99-102. http://dx.doi.org/10.1038/nature10358.
6. Chard L, Maniati E, Wang P, Zhang Z, Gao D, Wang J, Cao F, Ahmed J, Khouri ME, Hughes J, Wang S, Li X, Denes B, Fodor I, Hagemann T, Lemoine NR, Wang Y. 2015. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clin Cancer Res 21:405-416. http://dx.doi.org/10.1158/1078-0432.CCR-14-0464.
7. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. 2013. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19:329-336. http://dx.doi.org/10.1038/nm.3089.
8. Tysome JR, Briat A, Alusi G, Cao F, Gao D, Yu J, Wang P, Yang S, Dong Z, Wang S, Deng L, Francis J, Timiryasova T, Fodor I, Lemoine NR, Wang Y. 2009. Lister strain of vaccinia virus armed with endostatinangiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther 16:1223-1233. http://dx.doi.org/10.1038/gt.2009.74.
9. Weisswange I, Newsome TP, Schleich S, Way M. 2009. The rate of N-WASP exchange limits the extent of ARP2/3-complex-dependent actin-based motility. Nature 458:87-91. http://dx.doi.org/10.1038/nature07773.
10. Falkner FG, Moss B. 1990. Transient dominant selection of recombinant vaccinia viruses. J Virol 64:3108-3111.
11. Mackett M, Smith GL, Moss B. 1984. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 49:857-864.
12. Domi A, Moss B. 2002. Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci USA 99:12415-12420. http://dx.doi.org/10.1073/pnas.192420599.
13. Nakano E, Panicali D, Paoletti E. 1982. Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci USA 79:1593-1596. http://dx.doi.org/10.1073/pnas.79.5.1593.
14. Jansen R, Embden JD, Gaastra W, Schouls LM. 2002. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol 43:1565-1575. http://dx.doi.org/10.1046/j.1365-2958.2002.02839.x.
15. Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, Dickman MJ, Makarova KS, Koonin EV, van der Oost J. 2008. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321: 960-964. http://dx.doi.org/10.1126/science.1159689.
16. van der Oost J, Jore MM, Westra ER, Lundgren M, Brouns SJ. 2009. CRISPR-based adaptive and heritable immunity in prokaryotes. Trends Biochem Sci 34:401-407. http://dx.doi.org/10.1016/j.tibs.2009.05.002.
17. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819-823. http://dx.doi.org/10.1126/science.1231143.
18. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. Aprogrammabledual-RNA-guidedDNAendonuclease in adaptive bacterial immunity. Science 337:816-821. http://dx.doi.org/10.1126/science.1225829.
19. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X, Si W, Li W, Xiang AP, Zhou J, Guo X, Bi Y, Si C, Hu B, Dong G, Wang H, Zhou Z, Li T, Tan T, Pu X, Wang F, Ji S, Zhou Q, Huang X, Ji W, Sha J. 2014. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156:836-843. http://dx.doi.org/10.1016/j.cell.2014.01.027.
20. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. 2014. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32:551-553. http://dx.doi.org/10.1038/nbt.2884.
21. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. 2013. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153: 910-918. http://dx.doi.org/10.1016/j.cell.2013.04.025.
22. Bi Y, Sun L, Gao D, Ding C, Li Z, Li Y, Cun W, Li Q. 2014. High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog 10:e1004090. http://dx.doi.org/10.1371/journal.ppat.1004090.
23. Ahmed JY, Yuan M, Li YN, Chu YC, Shi HL, Chard L, Alusi G, Lemoine N, Wang Y. 2014. A novel tumour selective oncolytic vaccinia virus lacking the N1L gene enhances the anti-tumour immune response when used as an anticancer therapeutic. Mol Ther 22:S248-S249.
24. Bartlett N, Symons JA, Tscharke DC, Smith GL. 2002. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 83(Pt 8):1965-1976.
25. Billings B, Smith SA, Zhang Z, Lahiri DK, Kotwal GJ. 2004. Lack of N1L gene expression results in a significant decrease of vaccinia virus replication in mouse brain. Ann N Y Acad Sci 1030:297-302. http://dx.doi.org/10.1196/annals.1329.037.
26. Perdiguero B, Gomez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, Calandra T, Pantaleo G, Esteban M. 2013. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS One 8:e74831. http://dx.doi.org/10.1371/journal.pone.0074831.
27. Stack J, Haga IR, Schroder M, Bartlett NW, Maloney G, Reading PC, Fitzgerald KA, Smith GL, Bowie AG. 2005. Vaccinia virus proteinA46Rtargets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J ExpMed 201:1007-1018. http://dx.doi.org/10.1084/jem.20041442.